Proxygen

📍 Vienna, Austria👥 34 employees💰 Last funded Jan 2023
Biotechnology Research🌐 proxygen.com
Website LinkedIn
Proxygen is a Vienna-based startup that develops therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase. Consequently, the target protein is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete, targeted and selective elimination. This outlines a clear avenue towards targeting otherwise undruggable proteins and is therefore seen as one of the most promising innovations of the last decades.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Proxygen?
Proxygen has 1 investors on record on gritt.io.
When did Proxygen last raise funding?
The most recent investment in Proxygen recorded on gritt.io was in January 2023.
What industry is Proxygen in?
Proxygen operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Proxygen based?
Proxygen is headquartered in Vienna, Austria.